Last reviewed · How we verify
Placebos+chemo
A combination therapy pairing chemotherapy with placebo control to evaluate the efficacy of the chemotherapy agent in a Phase 3 clinical trial.
A combination therapy pairing chemotherapy with placebo control to evaluate the efficacy of the chemotherapy agent in a Phase 3 clinical trial. Used for Unspecified malignancy (specific indication not provided).
At a glance
| Generic name | Placebos+chemo |
|---|---|
| Also known as | Placebo |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a trial design rather than a single drug entity. Placebos+chemo refers to a randomized controlled study where one arm receives active chemotherapy while the control arm receives placebo, allowing researchers to isolate the true therapeutic effect of the chemotherapy component. This is standard methodology in oncology trials to establish efficacy and safety profiles.
Approved indications
- Unspecified malignancy (specific indication not provided)
Common side effects
Key clinical trials
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children (NA)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |